Massachusetts Institute of Technology

The General Hospital Corporation

Daniel Fass

Edward Holson

Stephen J Haggarty

Michael C Lewis

Jennifer Q Pan

Tracey Lynn Petryshen

Josh Ketterman

Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize &#x3b2;-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.

Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders

Growing community of inventors

Winchester, MA, United States of America

Daniel Fass